Neuromyelitis Optica Spectrum Disorder Clinical Trials in Wuhan, Hubei
4 recruitingWuhan, Hubei, China
Showing 1–4 of 4 trials
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders
Tongji Hospital69 enrolled1 locationNCT06620809
Recruiting
Early Phase 1
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557
Recruiting
Not Applicable
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
Multiple SclerosisAcute Disseminated EncephalomyelitisNeuromyelitis Optica Spectrum Disorder+2 more
Tongji Hospital250 enrolled1 locationNCT06474520